Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
bristol-myers squibb
8
×
life sciences
8
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
biotech
clinical trials
pfizer
biogen
cancer
celgene
merck
nonalcoholic steatohepatitis
abbvie
aducanumab
alzheimer's disease
cancer immunotherapy
deals
What
bio
drug
8
×
roundup
8
×
news
nash
week
advanced
alzheimer’s
approval
approved
biogen
biogen’s
companies
conference
disease
liver
medical
new
pricing
race
adu
aducanumab
advantages
alnylam’s
amyloid
angst
annual
arrival
assessed
attention
award
bagged
bar
beats
bff
bids
billions
biopharmaceutical
biotech
brammer
Language
unset
Current search:
drug
×
" life sciences "
×
roundup
×
" bristol-myers squibb "
×
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More